// App-Quantinova.ai

: The Therapeutic Response of Myelodsyplastic Syndromes to Azacytidine Is Independent of Endogenous Retroelement Modulation

Researchers

Presenter

  • Chrysoula Kordella

Principal Investigators

  • Anastasiya Kazachenka

  • Eleftheria Lamprianidou

  • Emmanouela Zoulia

  • George Vrachiolias

  • Menelaos Konstantinos Papoutselis

  • Zoe Bezirgiannidou

  • Emmanouil Spanoudakis

  • Christiana Georgiou

  • Urszula Eksmond

  • George Kassiotis

  • Ioannis Kotsianidis

Medical Centers

  • Department of Pneumonology, University Hospital of Alexandroupolis, Democritus University of Thrace, Komotini, Greece , Alexandroupolis, Greece

  • Retroviral Immunology,The Francis Crick Institute, 1 Midland Road,London NW1 1AT,United Kingdom

  • Department of Medicine, Faculty of Medicine, Imperial College London W2 1PG, UK, London, United Kingdom

Locations

  • Greece

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Chronic myelomonocytic leukemia

  • Myelodysplastic Syndrome

  • Acute myelocytic leukemia

Biomarkers

  • Cluster of Differentiation 34

  • Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Epsilon

  • DNA methylation

Drug/Treatment

  • Vidaza

  • Decitabine

  • Interferon

Outcome

  • N/A

Study Design

  • Double Blind/Blinded

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved